# Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration at Steady-state in Healthy Adult Volunteers

> **NCT02226991** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 34 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Tipranavir
- **DRUG:** Ritonavir
- **DRUG:** Efavirenz

## Key facts

- **NCT ID:** NCT02226991
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2006-07
- **Final completion:** —
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2014-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02226991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02226991, "Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration at Steady-state in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02226991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*